Celltrion announced on July 5 that its COVID-19 treatment Regkirona showed efficacy in treating the Brazilian gamma variants (P.2) as a result of conducting an animal efficacy test for Regkirona.
Celltrion injected Regkirona into 55 laboratory mice infected by Brazilian variants (gamma) and confirmed clinical improvements in the group treated with Regkirona, which showed a significant reduction in virus titer and weight loss defense, compared to the control group that did not receive any treatment.
In particular, the effectiveness of virus removal has been proven even when administered in a lower dose than the dose of human therapy.
In the case of experimental mice, the survival rate of the Regkirona administration group was 100 percent, while the survival rate of the non-treatment control group was 0 percent. This result is consistent with the previous Ferrets' results on South African variants (Beta).
Celltrion plans to continue to conduct cell-level neutralization and animal efficacy tests of Regkirona for various variants in the future in cooperation with trusted Korean and foreign organizations. It is also expected to secure results on animal efficacy tests in July for the ongoing India variants (Delta).
Meanwhile, "Regkirona" has been identified as having strong neutrality from cell-level against various variants such as UK (B.1.1.7), India (B.1.167), California (B.1.427/429), Nigeria (B.1.525), New York (B.1.526), and Brazil (P.1).
"The clinical efficacy of Regkirona on variants is being proven through animal efficacy tests," said an official of Celltrion. "We are also looking forward to have positive animal test results on India variants (Delta)."
